Newsroom
January 8, 2013
“You can learn a lot from studying a worm,” said Shane Rea, Ph.D., of the Barshop Institute for Longevity and Aging Studies, part of The University of Texas Health Science Center at San Antonio.
December 7, 2012
The ability of rapamycin-related drugs to potentially slow the aging process — suggested in animal experiments at The University of Texas Health Science Center San Antonio — has led to establishment of a new San Antonio biotech company, Rapamycin Holdings Inc., which is licensing exclusive rights to intellectual property central to several aspects of the rapamycin-related drugs.
August 30, 2012
Faculty from the Barshop Institute for Longevity and Aging Studies at the UT Health Science Center San Antonio contributed a core research service to a National Institute on Aging (NIA) study reported Aug. 29 online in Nature.
August 8, 2012
Fellowship program established with $200,000 gift from Glenn Foundation for Medical Research
July 25, 2012
Rapamycin, a drug used in transplant patients to prevent organ rejection, may reverse cardiac and skeletal muscle defects as well, a new mouse study published today in Science Translational Medicine suggests.
June 29, 2012
Rapamycin made young mice learn better and negated decline in old mice